Bristol-Myers Squibb Company (BMY): Today's Featured Drugs Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Bristol-Myers Squibb Company ( BMY) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 0.4%. By the end of trading, Bristol-Myers Squibb Company rose $1.25 (2.4%) to $53.84 on heavy volume. Throughout the day, 11,832,267 shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 7,135,800 shares. The stock ranged in a price between $52.92-$54.49 after having opened the day at $53.47 as compared to the previous trading day's close of $52.59. Other companies within the Drugs industry that increased today were: Alimera ( ALIM), up 62.8%, pSivida ( PSDV), up 35.0%, Oxygen Biotherapeutics ( OXBT), up 18.5% and Ariad Pharmaceuticals ( ARIA), up 10.8%.

Bristol-Myers Squibb Company, a biopharmaceutical company, discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products that help patients prevail over serious diseases worldwide. Bristol-Myers Squibb Company has a market cap of $84.1 billion and is part of the health care sector. The company has a P/E ratio of 30.8, above the S&P 500 P/E ratio of 17.7. Shares are up 61.4% year to date as of the close of trading on Wednesday. Currently there are 7 analysts that rate Bristol-Myers Squibb Company a buy, 1 analyst rates it a sell, and 7 rate it a hold.

TheStreet Ratings rates Bristol-Myers Squibb Company as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, compelling growth in net income, solid stock price performance, impressive record of earnings per share growth and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company shows weak operating cash flow.

On the negative front, CEL-SCI Corporation ( CVM), down 20.0%, Neogen Corporation ( NEOG), down 8.9%, Esperion Therapeutics ( ESPR), down 8.7% and Relypsa ( RLYP), down 7.1% , were all laggards within the drugs industry with Biogen Idec ( BIIB) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

More from Markets

Disney Tops Comcast Bid With Improved $71.3 Billion Approach for Fox

Disney Tops Comcast Bid With Improved $71.3 Billion Approach for Fox

5 Stocks That Are Screaming Buys Right Now

5 Stocks That Are Screaming Buys Right Now

General Electric Booted From Dow, Replaced by Walgreens

General Electric Booted From Dow, Replaced by Walgreens

European Union Says Tariffs on U.S. Imports Will Kick In on June 22

European Union Says Tariffs on U.S. Imports Will Kick In on June 22

Stocks Rise, GE Dropped From the Dow, Starbucks, Oracle - 5 Things You Must Know

Stocks Rise, GE Dropped From the Dow, Starbucks, Oracle - 5 Things You Must Know